PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT00273273
First received: January 4, 2006
Last updated: May 15, 2014
Last verified: April 2014

January 4, 2006
May 15, 2014
February 2006
December 2007   (final data collection date for primary outcome measure)
Measure the pharmacokinetics of atazanavir/ritonavir and tenofovir [ Time Frame: 6 Months ]
To measure the pharmacokinetics of atazanavir/ritonavir and tenofovir when used in combination to treat HIV-infected adolescents and young adult subjects
Not Provided
Complete list of historical versions of study NCT00273273 on ClinicalTrials.gov Archive Site
Kinetics comparison [ Time Frame: 6 Months ]
To compare the kinetics in these study subjects with published kinetics profiles in adults and children.
Not Provided
Not Provided
Not Provided
 
PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir
Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection

The purpose of this project is to study the pharmacokinetics of a once-daily antiretroviral medication used to treat adolescents and young adults with HIV infection.

Once-daily antiretroviral therapy is being used to treat adolescents and young adults with HIV-1 infection. When new antiretrovirals (ARVs) are developed, information on kinetics is collected in adults, and then in children, but often the adolescent age group is under-represented in initial or even later pharmacokinetics studies, so specific data on appropriate drug doses to use in adolescents may be lacking; it is assumed that they should receive the adult dose. Furthermore, as newer drugs are used in combination regimens, more information becomes available on drug interactions that might not have been initially anticipated. This information is usually generated in studies of adults, with little or no specific information in children or adolescents. This is an open-label, 24-hour, single-dose pharmacokinetic study.

Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample

Persons with HIV-1 infection between the ages of 18 years, 0 days and 24 years, 364 days currently on a stable combination antiretroviral regimen (> 28 days) with FDA-approved antiretroviral combination regimens that include tenofovir plus atazanavir/ritonavir and at least one other active antiretroviral drug.

HIV Infections
Procedure: blood draw
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
December 2007
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > 18 year to < 25 years.
  • Confirmed diagnosis of HIV-1 infection defined as one positive assay supported by documentation from the subject's medical record. The result may be any of the following:
  • HIV-1 DNA PCR,
  • HIV-1 RNA PCR (> 5,000 copies/ml),
  • Standard ELISA with confirmatory western blot performed after 18 months of age, or
  • HIV culture.
  • CD4 cell count: no restrictions.
  • Viral load: no restrictions.
  • Current treatment with stable antiretroviral combination therapy with at least 3 active drugs for a minimum of 28 days. The treatment regimen will not be started or changed for the purposes of participation in this study. Rather, this study will measure kinetics of the drugs in patients who have been receiving therapy at the direction of their treating physician.
  • Regimen must be prescribed at FDA-approved doses for age.
  • Regimens allowed:
  • Atazanavir 300 mg po once daily plus ritonavir 100 mg po once daily, and
  • Tenofovir 300 mg po once daily, plus
  • At least one other antiretroviral medication prescribed at FDA-approved dose for age, excluding other protease inhibitors and NNRTIs.
  • Ability and willingness to be contacted by study personnel daily for the two days prior to the pharmacokinetics visit, to take antiretroviral medicines at the same time in the morning daily for at least 3 days (one of those days being the day of the PK study visit), and ability and willingness to return to the clinic the day after the observed administered dose for a follow-up measurement of plasma drug concentration.
  • Ability and willingness to provide written informed consent.

Exclusion Criteria:

  • Pregnancy.
  • Active therapy for malignancy.
  • Known presence of gastrointestinal disease that would interfere with drug administration or absorption.
  • Grade 3 or higher ALT or AST.
  • Grade 3 or higher Creatinine.
  • Concurrent treatment with another protease inhibitor or a non-nucleoside analogue reverse transcriptase inhibitor.
  • No evidence of anemia greater than Grade 1 according to the ATN Toxicity Table for Grading Severity of Adolescent Adverse Experiences (see Chapter 11 of ATN MOGO).
Both
18 Years to 25 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00273273
ATN 056
No
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Institute on Drug Abuse (NIDA)
  • National Institute of Mental Health (NIMH)
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Study Chair: Peter Havens, MD MACC Fund Research Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP